Antiviral efficacy analysis of telbivudine concurrent with the first cycle of chemotherapy in HBsAg-positive lymphoma patients
Highlights • Telbivudine concurrent with initial chemotherapy can reduce HBV reactivation. • Telbivudine concurrent with chemotherapy was still effective when rituximab was used. • Even if baseline HBV viral loads are high, concurrent treatment is also effective.
Gespeichert in:
| Veröffentlicht in: | Journal of clinical virology 2014-10, Vol.61 (2), p.199-203 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 203 |
|---|---|
| container_issue | 2 |
| container_start_page | 199 |
| container_title | Journal of clinical virology |
| container_volume | 61 |
| creator | Li, Wenyu Huang, Ling Guo, Hanguo Wei, Xiaojuan Liang, Zhanli |
| description | Highlights • Telbivudine concurrent with initial chemotherapy can reduce HBV reactivation. • Telbivudine concurrent with chemotherapy was still effective when rituximab was used. • Even if baseline HBV viral loads are high, concurrent treatment is also effective. |
| doi_str_mv | 10.1016/j.jcv.2014.07.005 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1639985952</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S1386653214002686</els_id><sourcerecordid>1562441723</sourcerecordid><originalsourceid>FETCH-LOGICAL-c511t-720f6eefa811f02880693c7eb689cdda9fee95b6433c0999fa7c89983a4c13fc3</originalsourceid><addsrcrecordid>eNqFkj2P1DAQhiME4o6DH0CDXNIk-CNxYiEh7Z2AQzqJAqgt72TMenHiYCeL0vDbcbQHBQVUtqxnXmvmmaJ4zmjFKJOvjtURThWnrK5oW1HaPCguWdeKslGyfZjvopOlbAS_KJ6kdKSUNaJuHxcXvGG8E4pdFj934-xOLhpP0FoHBlZiRuPX5BIJlszo9-609G5EAmGEJUYcZ_LDzQcyH5BYF9NMYAWPGw4HHEJ-j2ZaiRvJ7XXafS2nkFz-BYlfh-kQBkMmM7uck54Wj6zxCZ_dn1fFl3dvP9_clncf33-42d2V0DA2ly2nViJa0zFmKe86KpWAFveyU9D3RllE1exlLQRQpZQ1LXRKdcLUwIQFcVW8POdOMXxfMM16cAnQezNiWJJmUmS8UQ3_P9pIXtes5SKj7IxCDClFtHqKbjBx1YzqzZA-6mxIb4Y0bXU2lGte3Mcv-wH7PxW_lWTg9RnAPI-Tw6gT5FkB9i4izLoP7p_xb_6qBu_G7NV_wxXTMSwx281d6MQ11Z-2Fdk2hNWUctlJ8QuiGbhY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1562441723</pqid></control><display><type>article</type><title>Antiviral efficacy analysis of telbivudine concurrent with the first cycle of chemotherapy in HBsAg-positive lymphoma patients</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Li, Wenyu ; Huang, Ling ; Guo, Hanguo ; Wei, Xiaojuan ; Liang, Zhanli</creator><creatorcontrib>Li, Wenyu ; Huang, Ling ; Guo, Hanguo ; Wei, Xiaojuan ; Liang, Zhanli</creatorcontrib><description>Highlights • Telbivudine concurrent with initial chemotherapy can reduce HBV reactivation. • Telbivudine concurrent with chemotherapy was still effective when rituximab was used. • Even if baseline HBV viral loads are high, concurrent treatment is also effective.</description><identifier>ISSN: 1386-6532</identifier><identifier>EISSN: 1873-5967</identifier><identifier>DOI: 10.1016/j.jcv.2014.07.005</identifier><identifier>PMID: 25128391</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Adolescent ; Adult ; Aged ; Allergy and Immunology ; Antineoplastic Agents - adverse effects ; Antineoplastic Agents - therapeutic use ; Antiviral Agents - therapeutic use ; Antiviral therapy ; Female ; HBsAg-positive lymphoma ; HBV reactivation ; Hepatitis B Surface Antigens - blood ; Hepatitis B virus ; Hepatitis B, Chronic - complications ; Hepatitis B, Chronic - drug therapy ; Humans ; Immunocompromised Host ; Infectious Disease ; Lymphoma - complications ; Lymphoma - drug therapy ; Male ; Middle Aged ; Retrospective Studies ; Telbivudine ; Telbivudine concurrent with chemotherapy ; Thymidine - analogs & derivatives ; Thymidine - therapeutic use ; Treatment Outcome ; Virus Activation - drug effects ; Young Adult</subject><ispartof>Journal of clinical virology, 2014-10, Vol.61 (2), p.199-203</ispartof><rights>Elsevier B.V.</rights><rights>2014 Elsevier B.V.</rights><rights>Copyright © 2014 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c511t-720f6eefa811f02880693c7eb689cdda9fee95b6433c0999fa7c89983a4c13fc3</citedby><cites>FETCH-LOGICAL-c511t-720f6eefa811f02880693c7eb689cdda9fee95b6433c0999fa7c89983a4c13fc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1386653214002686$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25128391$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Li, Wenyu</creatorcontrib><creatorcontrib>Huang, Ling</creatorcontrib><creatorcontrib>Guo, Hanguo</creatorcontrib><creatorcontrib>Wei, Xiaojuan</creatorcontrib><creatorcontrib>Liang, Zhanli</creatorcontrib><title>Antiviral efficacy analysis of telbivudine concurrent with the first cycle of chemotherapy in HBsAg-positive lymphoma patients</title><title>Journal of clinical virology</title><addtitle>J Clin Virol</addtitle><description>Highlights • Telbivudine concurrent with initial chemotherapy can reduce HBV reactivation. • Telbivudine concurrent with chemotherapy was still effective when rituximab was used. • Even if baseline HBV viral loads are high, concurrent treatment is also effective.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Allergy and Immunology</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Antiviral therapy</subject><subject>Female</subject><subject>HBsAg-positive lymphoma</subject><subject>HBV reactivation</subject><subject>Hepatitis B Surface Antigens - blood</subject><subject>Hepatitis B virus</subject><subject>Hepatitis B, Chronic - complications</subject><subject>Hepatitis B, Chronic - drug therapy</subject><subject>Humans</subject><subject>Immunocompromised Host</subject><subject>Infectious Disease</subject><subject>Lymphoma - complications</subject><subject>Lymphoma - drug therapy</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Retrospective Studies</subject><subject>Telbivudine</subject><subject>Telbivudine concurrent with chemotherapy</subject><subject>Thymidine - analogs & derivatives</subject><subject>Thymidine - therapeutic use</subject><subject>Treatment Outcome</subject><subject>Virus Activation - drug effects</subject><subject>Young Adult</subject><issn>1386-6532</issn><issn>1873-5967</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkj2P1DAQhiME4o6DH0CDXNIk-CNxYiEh7Z2AQzqJAqgt72TMenHiYCeL0vDbcbQHBQVUtqxnXmvmmaJ4zmjFKJOvjtURThWnrK5oW1HaPCguWdeKslGyfZjvopOlbAS_KJ6kdKSUNaJuHxcXvGG8E4pdFj934-xOLhpP0FoHBlZiRuPX5BIJlszo9-609G5EAmGEJUYcZ_LDzQcyH5BYF9NMYAWPGw4HHEJ-j2ZaiRvJ7XXafS2nkFz-BYlfh-kQBkMmM7uck54Wj6zxCZ_dn1fFl3dvP9_clncf33-42d2V0DA2ly2nViJa0zFmKe86KpWAFveyU9D3RllE1exlLQRQpZQ1LXRKdcLUwIQFcVW8POdOMXxfMM16cAnQezNiWJJmUmS8UQ3_P9pIXtes5SKj7IxCDClFtHqKbjBx1YzqzZA-6mxIb4Y0bXU2lGte3Mcv-wH7PxW_lWTg9RnAPI-Tw6gT5FkB9i4izLoP7p_xb_6qBu_G7NV_wxXTMSwx281d6MQ11Z-2Fdk2hNWUctlJ8QuiGbhY</recordid><startdate>20141001</startdate><enddate>20141001</enddate><creator>Li, Wenyu</creator><creator>Huang, Ling</creator><creator>Guo, Hanguo</creator><creator>Wei, Xiaojuan</creator><creator>Liang, Zhanli</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7T7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope></search><sort><creationdate>20141001</creationdate><title>Antiviral efficacy analysis of telbivudine concurrent with the first cycle of chemotherapy in HBsAg-positive lymphoma patients</title><author>Li, Wenyu ; Huang, Ling ; Guo, Hanguo ; Wei, Xiaojuan ; Liang, Zhanli</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c511t-720f6eefa811f02880693c7eb689cdda9fee95b6433c0999fa7c89983a4c13fc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Allergy and Immunology</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Antiviral therapy</topic><topic>Female</topic><topic>HBsAg-positive lymphoma</topic><topic>HBV reactivation</topic><topic>Hepatitis B Surface Antigens - blood</topic><topic>Hepatitis B virus</topic><topic>Hepatitis B, Chronic - complications</topic><topic>Hepatitis B, Chronic - drug therapy</topic><topic>Humans</topic><topic>Immunocompromised Host</topic><topic>Infectious Disease</topic><topic>Lymphoma - complications</topic><topic>Lymphoma - drug therapy</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Retrospective Studies</topic><topic>Telbivudine</topic><topic>Telbivudine concurrent with chemotherapy</topic><topic>Thymidine - analogs & derivatives</topic><topic>Thymidine - therapeutic use</topic><topic>Treatment Outcome</topic><topic>Virus Activation - drug effects</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Li, Wenyu</creatorcontrib><creatorcontrib>Huang, Ling</creatorcontrib><creatorcontrib>Guo, Hanguo</creatorcontrib><creatorcontrib>Wei, Xiaojuan</creatorcontrib><creatorcontrib>Liang, Zhanli</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>Journal of clinical virology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Li, Wenyu</au><au>Huang, Ling</au><au>Guo, Hanguo</au><au>Wei, Xiaojuan</au><au>Liang, Zhanli</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antiviral efficacy analysis of telbivudine concurrent with the first cycle of chemotherapy in HBsAg-positive lymphoma patients</atitle><jtitle>Journal of clinical virology</jtitle><addtitle>J Clin Virol</addtitle><date>2014-10-01</date><risdate>2014</risdate><volume>61</volume><issue>2</issue><spage>199</spage><epage>203</epage><pages>199-203</pages><issn>1386-6532</issn><eissn>1873-5967</eissn><abstract>Highlights • Telbivudine concurrent with initial chemotherapy can reduce HBV reactivation. • Telbivudine concurrent with chemotherapy was still effective when rituximab was used. • Even if baseline HBV viral loads are high, concurrent treatment is also effective.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>25128391</pmid><doi>10.1016/j.jcv.2014.07.005</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1386-6532 |
| ispartof | Journal of clinical virology, 2014-10, Vol.61 (2), p.199-203 |
| issn | 1386-6532 1873-5967 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1639985952 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adolescent Adult Aged Allergy and Immunology Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Antiviral Agents - therapeutic use Antiviral therapy Female HBsAg-positive lymphoma HBV reactivation Hepatitis B Surface Antigens - blood Hepatitis B virus Hepatitis B, Chronic - complications Hepatitis B, Chronic - drug therapy Humans Immunocompromised Host Infectious Disease Lymphoma - complications Lymphoma - drug therapy Male Middle Aged Retrospective Studies Telbivudine Telbivudine concurrent with chemotherapy Thymidine - analogs & derivatives Thymidine - therapeutic use Treatment Outcome Virus Activation - drug effects Young Adult |
| title | Antiviral efficacy analysis of telbivudine concurrent with the first cycle of chemotherapy in HBsAg-positive lymphoma patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T12%3A04%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antiviral%20efficacy%20analysis%20of%20telbivudine%20concurrent%20with%20the%20first%20cycle%20of%20chemotherapy%20in%20HBsAg-positive%20lymphoma%20patients&rft.jtitle=Journal%20of%20clinical%20virology&rft.au=Li,%20Wenyu&rft.date=2014-10-01&rft.volume=61&rft.issue=2&rft.spage=199&rft.epage=203&rft.pages=199-203&rft.issn=1386-6532&rft.eissn=1873-5967&rft_id=info:doi/10.1016/j.jcv.2014.07.005&rft_dat=%3Cproquest_cross%3E1562441723%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1562441723&rft_id=info:pmid/25128391&rft_els_id=1_s2_0_S1386653214002686&rfr_iscdi=true |